Brain+ A/S: peers
Brain+ A/S beside the 7 companies most like it by industry, size and country: every figure with its date and source, its rank in the group and its percentile in its sector and country.
Brain+ A/S, Monsenso A/S, Biodexa Pharmaceuticals plc, Virax Biolabs Group Limited, Stayble Therapeutics AB (publ), Lipidor AB (publ), Qlife Holding AB (publ), Lidds AB (publ): the market cap on file is more than 60 days old or a last known value (no market-data feed for their exchanges yet), so their valuation multiples and yields are shown but not ranked.
Side by side#
Every figure with its fiscal year or date and its source. Switch to each company's rank in the group, or its percentile in its sector or country. How ranks are worked out.
| Measure | Brain+ A/Sbase BRAINP.CO · 🇩🇰 DK Percentile in Healthcare Percentile in Denmark | Monsenso A/S MONSO.CO · 🇩🇰 DK Percentile in Healthcare Percentile in Denmark | Biodexa Pharmaceuticals plc BDRX · 🇬🇧 GB Percentile in Healthcare Percentile in UK | Virax Biolabs Group Limited VRAX · 🇬🇧 GB Percentile in Healthcare Percentile in UK | Stayble Therapeutics AB (publ) STABL.ST · 🇸🇪 SE Percentile in Healthcare Percentile in Sweden | Lipidor AB (publ) LIPI.ST · 🇸🇪 SE Percentile in Healthcare Percentile in Sweden | Qlife Holding AB (publ) QLIFE.ST · 🇸🇪 SE Percentile in Healthcare Percentile in Sweden | Lidds AB (publ) LIDDS.ST · 🇸🇪 SE Percentile in Healthcare Percentile in Sweden | Group median |
|---|---|---|---|---|---|---|---|---|---|
| Size | |||||||||
| Market cap (Better neither way: ranked highest first) | $1 Mlast known, Jan 5, 2024 · Market dataLast known value: no current one3rd of 8 | $1 Mlast known, Jan 5, 2024 · Market dataLast known value: no current one3rd of 8 | $1 MAug 1, 2026 · Market data2nd of 8 | $2 MAug 1, 2026 · Market data1st of 8 | $1 Mlast known, Jan 5, 2024 · Market dataLast known value: no current one3rd of 8 | $1 Mlast known, Jan 5, 2024 · Market dataLast known value: no current one3rd of 8 | $1 Mlast known, Jan 5, 2024 · Market dataLast known value: no current one3rd of 8 | $1 Mlast known, Jan 5, 2024 · Market dataLast known value: no current one3rd of 8 | $1 M8 ranked |
| Revenue (Better neither way: ranked highest first) | —— | —— | —— | $0 MFY2024 · SEConly one with it | —— | —— | —— | —— | $0 M— |
| Net income (Higher is better) | —— | —— | $-8 MFY2025 · SEC2nd of 2 | $-6 MFY2024 · SEC1st of 2 | —— | —— | —— | —— | $-7 M2 ranked |
| Employees (Better neither way: ranked highest first) | —— | —— | —— | 26March 31, 2026 · Profileonly one with it | —— | —— | —— | —— | 26— |
| Margins and returns | |||||||||
| Return on equity (Higher is better) | ———— | ———— | -65.2%FY2025 · SEC1st of 236th5th | -109.5%FY2024 · SEC2nd of 222nd3rd | ———— | ———— | ———— | ———— | -87.4%2 ranked |
| Valuation | |||||||||
| Price to sales (Better neither way: ranked highest first) | ———— | ———— | ———— | 200.0׆price Aug 1, 2026 · Market datanot ranked: old priceold priceold price | ———— | ———— | ———— | ———— | —— |
| Price to book (Better neither way: ranked highest first) | ———— | ———— | 0.1׆price Aug 1, 2026 · Market datanot ranked: old priceold priceold price | 0.3׆price Aug 1, 2026 · Market datanot ranked: old priceold priceold price | ———— | ———— | ———— | ———— | —— |
| Scorecard | |||||||||
| Scorecard (Higher is better) | —— | —— | 1 of 6FY2025 · Scorecard1st of 2 | 1 of 8FY2024 · Scorecard2nd of 2 | —— | —— | —— | —— | 15% passed2 ranked |
| Growth checks (Higher is better) | —— | —— | 1 of 2FY2025 · Scorecard1st of 2 | 0 of 1FY2024 · Scorecard2nd of 2 | —— | —— | —— | —— | 25% passed2 ranked |
| Profitability checks (Higher is better) | —— | —— | 0 of 3FY2025 · Scorecard1st of 2 | 0 of 3FY2024 · Scorecard1st of 2 | —— | —— | —— | —— | 0% passed2 ranked |
| Financial health checks (Higher is better) | —— | —— | 0 of 1FY2025 · Scorecard2nd of 2 | 1 of 3FY2024 · Scorecard1st of 2 | —— | —— | —— | —— | 17% passed2 ranked |
| Shareholder returns checks (Higher is better) | —— | —— | —— | 0 of 1FY2024 · Scorecardonly one with it | —— | —— | —— | —— | 0% passed— |
| Ownership | |||||||||
| Held by institutions (Better neither way: ranked highest first) | —— | —— | 11.2%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in1st of 2 | 4.9%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in2nd of 2 | —— | —— | —— | —— | 8.1%2 ranked |
| Institutions holding (Better neither way: ranked highest first) | —— | —— | 62026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in1st of 2 | 42026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in2nd of 2 | —— | —— | —— | —— | 52 ranked |
Under each figure: its fiscal year, quarter or date, and its source. ↑ higher is better, ↓ lower is better, · better neither way (ranked highest first). Ranks count only the companies with the figure; percentiles place each company among all the companies of its own sector and country with the figure (ten or more needed).
† The market cap behind this figure is more than 60 days old (no market-data feed for that exchange yet): it is shown but not ranked or given a percentile.
Sources: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Editors = The company's annual report, entered by value.today editors; Wikidata = Wikidata, citing the annual report; Scorecard = value.today scorecard: thirty checks on the company's statements, worked out daily; 13F = SEC Form 13F holdings reports; SEC = Dividends declared per share in SEC 10-Q and 10-K filings; Profile = The company's latest reported headcount; Market data = Brain+ A/S: How market caps are worked out; Monsenso A/S: How market caps are worked out; Biodexa Pharmaceuticals plc: How market caps are worked out; Virax Biolabs Group Limited: How market caps are worked out; Stayble Therapeutics AB (publ): How market caps are worked out; Lipidor AB (publ): How market caps are worked out; Qlife Holding AB (publ): How market caps are worked out; Lidds AB (publ): How market caps are worked out.
Where each stands in its sector and country: Return on equity#
The dot is the company; the line runs from the 10th to the 90th percentile of all the companies of its sector (or country) with the figure, the box holds the middle half and the tick is the median. Each company's newest fiscal year; figures that divide by the market value only with a market cap at most 60 days old. How percentiles are worked out.
| Company | Return on equity | In its sector | In its country |
|---|---|---|---|
| Brain+ A/S | — | — | — |
| Monsenso A/S | — | — | — |
| Biodexa Pharmaceuticals plc | -65.2%FY2025 | 36th percentile in Healthcaremedian -36.9%, 977 companies | 5th percentile in UKmedian 7.7%, 417 companies |
| Virax Biolabs Group Limited | -109.5%FY2024 | 22nd percentile in Healthcaremedian -36.9%, 977 companies | 3rd percentile in UKmedian 7.7%, 417 companies |
| Stayble Therapeutics AB (publ) | — | — | — |
| Lipidor AB (publ) | — | — | — |
| Qlife Holding AB (publ) | — | — | — |
| Lidds AB (publ) | — | — | — |
Revenue by fiscal year, and the rank in the group#
Revenue of the fiscal year. US dollars at each year's exchange rate; fiscal years as each company names them. Ranks: 1st is the highest (better neither way).
Revenue
Rank in the group
| Fiscal year | Brain+ A/S | Monsenso A/S | Biodexa Pharmaceuticals plc | Virax Biolabs Group Limited | Stayble Therapeutics AB (publ) | Lipidor AB (publ) | Qlife Holding AB (publ) | Lidds AB (publ) |
|---|---|---|---|---|---|---|---|---|
| 2024 | — | — | — | $0 MSEC | — | — | — | — |
| 2023 | — | — | $0 MSEC | — | — | — | — | — |
| 2022 | — | — | $1 MSEC1st | $0 MSEC2nd | — | — | — | — |
| 2021 | — | — | $1 MSEC | — | — | — | — | — |
| 2020 | — | — | $0 MSEC1st | $0 MSEC2nd | — | — | — | — |
| 2019 | — | — | $1 MSEC | — | — | — | — | — |
| 2018 | — | — | $3 MSEC | — | — | — | — | — |
| 2017 | — | — | $1 MSEC | — | — | — | — | — |
| 2016 | — | — | $2 MSEC | — | — | — | — | — |
| 2015 | — | — | $2 MSEC | — | — | — | — | — |
Sources: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Ed. = The company's annual report, entered by value.today editors; WD = Wikidata, citing the annual report; Cap = value.today market caps (the last of each calendar year). The small ordinal is the rank in the group that year. Hover a figure for its fiscal year end.
Suggested peers of Brain+ A/S#
Companies of the same industry first, then the same sector, within a hundred times its size (market cap), scored out of 100 for industry, size, country and figures on file. How peers are suggested.
- Monsenso A/SMONSO.CO · 🇩🇰 DenmarkSame sector: Healthcare (Healthcare Information Services) · Similar size: $1 M market cap against $1 M · Same country: DenmarkMarket cap $1 M (last known, Jan 5, 2024)70 of 100 (industry or sector 25 + size 30 + country 15)In the group
- Biodexa Pharmaceuticals plcBDRX · 🇬🇧 UKSame sector: Healthcare (Biotechnology) · Similar size: $1 M market cap against $1 M · Same region: Northern Europe · Ratios of the last two fiscal years on fileMarket cap $1 M (Aug 1, 2026)66 of 100 (industry or sector 25 + size 29 + country 7 + figures on file 5)In the group
- Virax Biolabs Group LimitedVRAX · 🇬🇧 UKSame sector: Healthcare (Diagnostics and Research) · Similar size: $2 M market cap against $1 M · Same region: Northern Europe · Ratios of the last two fiscal years on fileMarket cap $2 M (Aug 1, 2026) · revenue $0 M (year to March 2025)62 of 100 (industry or sector 25 + size 26 + country 7 + figures on file 5)In the group
- Stayble Therapeutics AB (publ)STABL.ST · 🇸🇪 SwedenSame sector: Healthcare (Biotechnology) · Similar size: $1 M market cap against $1 M · Same region: Northern EuropeMarket cap $1 M (last known, Jan 5, 2024)62 of 100 (industry or sector 25 + size 30 + country 7)In the group
- Lipidor AB (publ)LIPI.ST · 🇸🇪 SwedenSame sector: Healthcare (Pharmaceutical) · Similar size: $1 M market cap against $1 M · Same region: Northern EuropeMarket cap $1 M (last known, Jan 5, 2024)62 of 100 (industry or sector 25 + size 30 + country 7)In the group
- Qlife Holding AB (publ)QLIFE.ST · 🇸🇪 SwedenSame sector: Healthcare (Medical Devices) · Similar size: $1 M market cap against $1 M · Same region: Northern EuropeMarket cap $1 M (last known, Jan 5, 2024)62 of 100 (industry or sector 25 + size 30 + country 7)In the group
- Lidds AB (publ)LIDDS.ST · 🇸🇪 SwedenSame sector: Healthcare (Biotechnology) · Similar size: $1 M market cap against $1 M · Same region: Northern EuropeMarket cap $1 M (last known, Jan 5, 2024)62 of 100 (industry or sector 25 + size 30 + country 7)In the group
- Diagonal Bio AB (publ)DIABIO.ST · 🇸🇪 SwedenSame sector: Healthcare (Biotechnology) · Similar size: $1 M market cap against $1 M · Same region: Northern EuropeMarket cap $1 M (last known, Jan 5, 2024)62 of 100 (industry or sector 25 + size 30 + country 7)+ Add
- Idogen AB (publ)IDOGEN.ST · 🇸🇪 SwedenSame sector: Healthcare (Biotechnology) · Similar size: $1 M market cap against $1 M · Same region: Northern EuropeMarket cap $1 M (last known, Dec 25, 2022)62 of 100 (industry or sector 25 + size 30 + country 7)+ Add
- Promore Pharma AB (publ)PROMO.ST · 🇸🇪 SwedenSame sector: Healthcare (Biotechnology) · Similar size: $1 M market cap against $1 M · Same region: Northern EuropeMarket cap $1 M (last known, Jan 5, 2024)62 of 100 (industry or sector 25 + size 30 + country 7)+ Add
- Pharmacolog I Uppsala AB (publ)PHLOG-B.ST · 🇸🇪 SwedenSame sector: Healthcare (Medical Equipment) · Similar size: $1 M market cap against $1 M · Same region: Northern EuropeMarket cap $1 M (last known, Jul 30, 2023)62 of 100 (industry or sector 25 + size 30 + country 7)+ Add
- Pharmiva AB (publ)PHARM.ST · 🇸🇪 SwedenSame sector: Healthcare (Biotechnology) · Similar size: $1 M market cap against $1 M · Same region: Northern EuropeMarket cap $1 M (last known, Jul 30, 2023)62 of 100 (industry or sector 25 + size 30 + country 7)+ Add
Any figure over the years, other peers or a saved group: open this group in the peer workspace.